Peter Czabotar, a structural biologist, obtained his PhD from Curtin University in Perth, Australia, followed by post-doctoral research at the National Institute for Medical Research in London, UK. He subsequently moved to WEHI to focus on cell death proteins and drug discovery and was part of the team that developed Venetoclax. Peter was co-awarded the Eureka Prize for Innovation in Medical Research in 2016 and the ATSE Clunies Ross Commercialisation Award in 2018. In 2015 he received the Gottschalk Medal, Awarded by the Australian Academy of Science, for his work on cell death proteins. He is currently joint head of the Structural Biology Division at the Walter and Eliza Hall Institute of Medical Research.